Analisis Biaya Langsung dan Biaya Tidak Langsung Penderita Hipertensi pada Masyarakat Wilayah Hutan Tropis Lembap di Kota Samarinda

Chaerunnisa AR; Ratno  Adrianto; Reza Nur  Fahmi; La  Suhani

doi:10.62159/kenduri.v6i1.2119

Chaerunnisa AR Universitas Mulawarman
Ratno Adrianto Universitas Mulawarman, Samarinda, Indonesia
Reza Nur Fahmi Universitas Mulawarman, Samarinda, Indonesia
La Suhani Universitas Mulawarman, Samarinda, Indonesia

DOI: https://doi.org/10.62159/kenduri.v6i1.2119

Keywords: Cost of Illness, Hypertension, Direct Costs, Indirect Costs, Productivity Loss, BPJS, Samarinda City

Abstract

Hypertension is the leading non-communicable disease (NCD) in Samarinda City, imposing a considerable economic burden on patients and their families. This study aimed to analyze direct and indirect costs borne by hypertension patients in the humid tropical forest area of Samarinda City. A quantitative descriptive observational study with a cross-sectional design was conducted involving 370 respondents recruited via purposive sampling from 10 community health centers (Puskesmas) across Samarinda. Data were collected through structured interviews covering direct costs (outpatient fees, inpatient expenses, and other out-of-pocket medical costs) and indirect costs (transportation, assistive devices, and productivity loss for both patients and caregivers). Results showed that the average annual direct cost per patient was IDR 1,236,345, dominated by routine outpatient and alternative treatment expenses. The average annual indirect cost was IDR 2,177,808, with productivity loss being the largest component. Indirect costs significantly exceeded direct costs, highlighting the hidden economic burden of hypertension. All respondents were JKN/BPJS participants, yet out-of-pocket expenditures remained substantial. These findings emphasize the need for comprehensive hypertension control programs that address both medical and non-medical economic burdens.

References

Adane, A., Atnafu, A., & Mohammed, S. (2020). The cost of illness of hypertension and associated factors at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia. ClinicoEconomics and Outcomes Research, 12, 133–141.

Baroroh, F., & Fauziah, S. S. (2017). Biaya medik langsung terapi hipertensi pasien rawat jalan di rumah sakit X Yogyakarta. Jurnal Farmasi Sains dan Praktis, 3(2), 6–13.

Dinas Kesehatan Kota Samarinda. (2022). Profil Kesehatan Kota Samarinda Tahun 2022. Samarinda: Dinas Kesehatan Kota Samarinda.

Etika, T., Pristianty, L., & Hidayati, I. R. (2020). Analisis cost of illness pada pasien hipertensi peserta BPJS rawat jalan di Puskesmas Banyuanyar. Pharmaceutical Journal of Indonesia, 6(1), 41–46.

Fathonah, U., Eka Rini, W. N., Hidayati, F., Syukri, M., & Eka Putri, F. (2025). Direct cost analysis of hypertension in national health insurance participants for the advanced level healthcare in Indonesia: Analysis of BPJS Kesehatan Sample Data 2023. International Journal of Health Science, 5(2).

Finkelstein, E. A., Chay, J., & Bajpai, S. (2014). The economic burden of self-reported and undiagnosed cardiovascular diseases and diabetes on Indonesian households. PLOS ONE, 9(6), e99572. https://doi.org/10.1371/journal.pone.0099572

Marbun, M., Solida, A., & Wardiah, R. (2023). Gambaran cost of illness dari perspektif pasien hipertensi rawat jalan. Jurnal Ilmiah Permas: Jurnal Ilmiah STIKES Kendal, 14(1), 125–136. https://doi.org/10.32583/pskm.v14i1.1256

Mashuri, Y. A., Ng, N., & Santosa, A. (2022). Socioeconomic disparities in the burden of hypertension among Indonesian adults: A multilevel analysis. Global Health Action, 15(1), 2129131. https://doi.org/10.1080/16549716.2022.2129131

Musakkar, & Djafar, M. (2021). Faktor-faktor risiko hipertensi. Jurnal Ilmiah Kesehatan Masyarakat, 13(2), 45–55.

Nurwinda Sari, N., Dewi Yuliana, Annisa Agata, & Henni Febriawati. (2023). Faktor karakteristik responden yang berhubungan dengan manajemen pengendalian hipertensi. Jurnal Keperawatan, 15(1), 69–76.

World Health Organization. (2009). Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva: WHO Press.

World Health Organization. (2019). Hypertension. Geneva: WHO. Retrieved from https://www.who.int/news-room/fact-sheets/detail/hypertension.

Kharazi, A. R., & Raharjo, B. B. (2025). Direct cost analysis of hypertension in national health insurance participants for advanced level healthcare in Indonesia: Analysis of BPJS Kesehatan sample data 2023. International Journal of Health Science, 5(2), 7–20.

Istiqomah, N. (2024). Analisis efektivitas biaya penggunaan obat antihipertensi pada pasien hipertensi. Jurnal Riset Ilmu Kefarmasian.

Lolo, W. A., Wiyono, W. I., & Mpila, D. A. (2024). Cost of illness pasien hipertensi rawat inap di RSUP Prof. Dr. R. D. Kandou Manado. E-CliniC, 12(3).

Mulianingsih, M., Endarti, D., & Wahyuni, A. (2021). Biaya langsung dan tidak langsung pada penyakit hipertensi: Narrative review. Jurnal Surya Medika.

Andriani, Y., Wulandari, S., & Larasati, N. (2025). Cost of illness pada pasien hipertensi rawat jalan di Puskesmas Gamping 2. Jurnal Ekonomi Kesehatan Indonesia, 10(1).

Daroudi, R., Akbari Sari, A., Zamani, M., & Shahali, Z. (2025). Economic burden of hypertension: A prevalence-based study in Iran. BMJ Open, 15(6), e099322. https://doi.org/10.1136/bmjopen-2025-099322

Dalaba, M. A., Doegah, P. T., Folsom, A. A., Immurana, M., & Ayanore, M. A. (2025). Economic burden of hypertension among outpatients in Ghana. BMC Health Services Research, 25, 1116. https://doi.org/10.1186/s12913-025-13338-9

Dinasari, B. P., Suryanegara, F. D. A., & Nugraheni, D. A. (2021). Cost consequences analysis of hypertensive patients in outpatient settings. Jurnal Ilmiah Farmasi, 17(2), 115–126.

Mulianingsih, B. R. N., Endarti, D., & Widayanti, A. W. (2021). Analisis biaya langsung dan tidak langsung pada penyakit hipertensi: Narrative review. Jurnal Surya Medika, 7(1), 99–106.